BCYC · Bicycle Therapeutics PLC
Market Cap
$270.17M
Shares
69.99M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$3.86
Open$3.87
Day$3.83–3.96
52W close$3.83–8.87
Avg vol 30d350K
Short int3.3M · 4.7% float · 13.8d
Short vol33%
Last earningsOct 30, 2025
DataJan 2020–Sep 2026
Filing10-Q · Jul 30
Up next
filed Jul 30, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$61.20M
Trailing 12 months
Net income (TTM)
−$190.41M
Trailing 12 months
Revenue growth YoY
-78.5%
Year over year
Operating margin
-343.6%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-77.1%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+0.8%
Year over year · more shares
Price change (1Y)
-45.0%
Trailing year
Short interest
4.7%
Latest settlement · 13.8 days to cover
Equibles Rating
blended score · not investment adviceOverall
Strong Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 15.8 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−25%
below
Price vs 50-day avg
−7%
below
RSI (14)
39
neutral
MACD trend
Negative
52-week position
1%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−3%
trailing
6-month return
−11%
trailing
YTD return
−45%
this year
Relative strength
−29%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $4 › 200d $5 — 200d above 50d
Institutional flow
Accumulating
+5% holders QoQ · +18 funds added
Insider flow
Distributing
Net -$54.4K over 90 days · 100% sells
Short interest
Rising
4.69% of float · ▲ +1.8% MoM · 13.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
103 holders — mid 3-yr range
Squeeze score
55
elevated · 0–100
Fundamentals
Revenue growth
+106%
Y/Y
EPS growth
−9%
Y/Y
Free cash flow
$-252.0M
Balance sheet
$495.7M
net cash
Quant / Vol
risk profile
Volatility
52%
annualized · 1-yr
Max drawdown
−57%
past year
ATR
4.5%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Apr 30, 2026
Annual operating expenses
· current plans
50%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−25%
Bearish
Price vs 50-day avg
−7%
Bearish
RSI (14)
39
Neutral
MACD trend
Negative
Bearish
52-week position
1%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $4 › 200d $5 — 200d above 50d
Institutional flow
Accumulating
+5% holders QoQ · +18 funds added
Insider flow
Distributing
Net -$54.4K over 90 days · 100% sells
Short interest
Rising
4.69% of float · ▲ +1.8% MoM · 13.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
103 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $4
Now $4 · 1%
Range high $9
vs 200-day avg -25%
vs 50-day avg -7%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
BCYC
this stock
Bicycle Therapeutics PLC
|
$270.17M | -45.5% | +105.8% | — | 4.7% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$130.64B | +13.7% | +46.2% | 30.0 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$80.46B | +1.2% | +20.8% | 19.4 | 2.5% |
|
ARGX
Argenx SE
|
$61.22B | +17.1% | — | — | 2.0% |
|
MRNA
Moderna, Inc.
|
$57.48B | +388.2% | +4.3% | — | 9.8% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| BCYC | -9.0% | -3.0% | -11.3% | -6.5% | -45.5% |
| SPY | -1.2% | -1.8% | +17.8% | -0.4% | +12.1% |
| vs SPY | -7.8% | -1.3% | -29.1% | -6.2% | -57.6% |
Key facts
CIK
1761612
CUSIP
088786108
13F (30d)
48 filings
48 filers
Visit website
Investor relations